Charles River Laboratories International, Inc.
CRL
$163.71
-$0.40-0.24%
NYSE
| 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.03B | 4.02B | 4.05B | 4.06B | 4.08B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.03B | 4.02B | 4.05B | 4.06B | 4.08B |
| Cost of Revenue | 2.62B | 2.63B | 2.65B | 2.62B | 2.63B |
| Gross Profit | 1.41B | 1.39B | 1.40B | 1.44B | 1.45B |
| SG&A Expenses | 743.59M | 723.62M | 724.52M | 724.41M | 711.38M |
| Depreciation & Amortization | 129.07M | 132.16M | 127.87M | 120.67M | 122.50M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.50B | 3.49B | 3.50B | 3.46B | 3.46B |
| Operating Income | 532.52M | 533.59M | 549.66M | 597.44M | 616.95M |
| Income Before Tax | -18.15M | 30.08M | 93.11M | 518.61M | 540.24M |
| Income Tax Expenses | 46.73M | 53.39M | 67.82M | 90.62M | 94.53M |
| Earnings from Continuing Operations | -64.88 | -23.31 | 25.29 | 427.99 | 445.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.16M | -1.98M | -3.09M | -4.21M | -4.20M |
| Net Income | -67.04M | -25.29M | 22.20M | 423.78M | 441.51M |
| EBIT | 532.52M | 533.59M | 549.66M | 597.44M | 616.95M |
| EBITDA | 953.29M | 885.44M | 902.00M | 937.59M | 947.78M |
| EPS Basic | -1.31 | -0.63 | 0.17 | 8.04 | 8.40 |
| Normalized Basic EPS | 4.86 | 4.76 | 5.06 | 5.92 | 6.01 |
| EPS Diluted | -1.33 | -0.65 | 0.15 | 7.99 | 8.35 |
| Normalized Diluted EPS | 4.85 | 4.74 | 5.03 | 5.89 | 5.97 |
| Average Basic Shares Outstanding | 202.36M | 204.76M | 205.52M | 205.69M | 205.58M |
| Average Diluted Shares Outstanding | 202.89M | 205.42M | 206.34M | 206.83M | 206.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |